Serveur d'exploration sur la rapamycine et les champignons

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.

Identifieur interne : 001300 ( Main/Exploration ); précédent : 001299; suivant : 001301

Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.

Auteurs : Linda S. Steelman [États-Unis] ; Patrick Navolanic ; William H. Chappell ; Stephen L. Abrams ; Ellis W T. Wong ; Alberto M. Martelli ; Lucio Cocco ; Franca Stivala ; Massimo Libra ; Ferdinando Nicoletti ; Lyudmyla B. Drobot ; Richard A. Franklin ; James A. Mccubrey

Source :

RBID : pubmed:21869603

Descripteurs français

English descriptors

Abstract

Elucidating the response of breast cancer cells to chemotherapeutic and hormonal based drugs and radiation is clearly important as these are common treatment approaches. Signaling cascades often involved in chemo-, hormonal- and radiation resistance are the Ras/PI3K/PTEN/Akt/mTOR, Ras/Raf/MEK/ERK and p53 pathways. In the following studies we have examined the effects of activation of the Ras/PI3K/PTEN/Akt/mTOR cascade in the response of MCF-7 breast cancer cells to chemotherapeutic- and hormonal-based drugs and radiation. Activation of Akt by introduction of conditionally-activated Akt-1 gene could result in resistance to chemotherapeutic and hormonal based drugs as well as radiation. We have determined that chemotherapeutic drugs such as doxorubicin or the hormone based drug tamoxifen, both used to treat breast cancer, resulted in the activation of the Raf/MEK/ERK pathway which is often associated with a pro-proliferative, anti-apoptotic response. In drug sensitive MCF-7 cells which have wild-type p53; ERK, p53 and downstream p21 (Cip-1 ) were induced upon exposure to doxorubicin. In contrast, in the drug resistant cells which expressed activated Akt-1, much lower levels of p53 and p21 (Cip1) were induced upon exposure to doxorubicin. These results indicate the involvement of the Ras/PI3K/PTEN/Akt/mTOR, Ras/Raf/MEK/ERK and p53 pathways in the response to chemotherapeutic and hormonal based drugs. Understanding how breast cancers respond to chemo- and hormonal-based therapies and radiation may enhance the ability to treat breast cancer more effectively.

DOI: 10.4161/cc.10.17.17119
PubMed: 21869603
PubMed Central: PMC3218601


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.</title>
<author>
<name sortKey="Steelman, Linda S" sort="Steelman, Linda S" uniqKey="Steelman L" first="Linda S" last="Steelman">Linda S. Steelman</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC</wicri:regionArea>
<placeName>
<region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Navolanic, Patrick" sort="Navolanic, Patrick" uniqKey="Navolanic P" first="Patrick" last="Navolanic">Patrick Navolanic</name>
</author>
<author>
<name sortKey="Chappell, William H" sort="Chappell, William H" uniqKey="Chappell W" first="William H" last="Chappell">William H. Chappell</name>
</author>
<author>
<name sortKey="Abrams, Stephen L" sort="Abrams, Stephen L" uniqKey="Abrams S" first="Stephen L" last="Abrams">Stephen L. Abrams</name>
</author>
<author>
<name sortKey="Wong, Ellis W T" sort="Wong, Ellis W T" uniqKey="Wong E" first="Ellis W T" last="Wong">Ellis W T. Wong</name>
</author>
<author>
<name sortKey="Martelli, Alberto M" sort="Martelli, Alberto M" uniqKey="Martelli A" first="Alberto M" last="Martelli">Alberto M. Martelli</name>
</author>
<author>
<name sortKey="Cocco, Lucio" sort="Cocco, Lucio" uniqKey="Cocco L" first="Lucio" last="Cocco">Lucio Cocco</name>
</author>
<author>
<name sortKey="Stivala, Franca" sort="Stivala, Franca" uniqKey="Stivala F" first="Franca" last="Stivala">Franca Stivala</name>
</author>
<author>
<name sortKey="Libra, Massimo" sort="Libra, Massimo" uniqKey="Libra M" first="Massimo" last="Libra">Massimo Libra</name>
</author>
<author>
<name sortKey="Nicoletti, Ferdinando" sort="Nicoletti, Ferdinando" uniqKey="Nicoletti F" first="Ferdinando" last="Nicoletti">Ferdinando Nicoletti</name>
</author>
<author>
<name sortKey="Drobot, Lyudmyla B" sort="Drobot, Lyudmyla B" uniqKey="Drobot L" first="Lyudmyla B" last="Drobot">Lyudmyla B. Drobot</name>
</author>
<author>
<name sortKey="Franklin, Richard A" sort="Franklin, Richard A" uniqKey="Franklin R" first="Richard A" last="Franklin">Richard A. Franklin</name>
</author>
<author>
<name sortKey="Mccubrey, James A" sort="Mccubrey, James A" uniqKey="Mccubrey J" first="James A" last="Mccubrey">James A. Mccubrey</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2011">2011</date>
<idno type="RBID">pubmed:21869603</idno>
<idno type="pmid">21869603</idno>
<idno type="pmc">PMC3218601</idno>
<idno type="doi">10.4161/cc.10.17.17119</idno>
<idno type="wicri:Area/Main/Corpus">001259</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001259</idno>
<idno type="wicri:Area/Main/Curation">001259</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001259</idno>
<idno type="wicri:Area/Main/Exploration">001259</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.</title>
<author>
<name sortKey="Steelman, Linda S" sort="Steelman, Linda S" uniqKey="Steelman L" first="Linda S" last="Steelman">Linda S. Steelman</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC</wicri:regionArea>
<placeName>
<region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Navolanic, Patrick" sort="Navolanic, Patrick" uniqKey="Navolanic P" first="Patrick" last="Navolanic">Patrick Navolanic</name>
</author>
<author>
<name sortKey="Chappell, William H" sort="Chappell, William H" uniqKey="Chappell W" first="William H" last="Chappell">William H. Chappell</name>
</author>
<author>
<name sortKey="Abrams, Stephen L" sort="Abrams, Stephen L" uniqKey="Abrams S" first="Stephen L" last="Abrams">Stephen L. Abrams</name>
</author>
<author>
<name sortKey="Wong, Ellis W T" sort="Wong, Ellis W T" uniqKey="Wong E" first="Ellis W T" last="Wong">Ellis W T. Wong</name>
</author>
<author>
<name sortKey="Martelli, Alberto M" sort="Martelli, Alberto M" uniqKey="Martelli A" first="Alberto M" last="Martelli">Alberto M. Martelli</name>
</author>
<author>
<name sortKey="Cocco, Lucio" sort="Cocco, Lucio" uniqKey="Cocco L" first="Lucio" last="Cocco">Lucio Cocco</name>
</author>
<author>
<name sortKey="Stivala, Franca" sort="Stivala, Franca" uniqKey="Stivala F" first="Franca" last="Stivala">Franca Stivala</name>
</author>
<author>
<name sortKey="Libra, Massimo" sort="Libra, Massimo" uniqKey="Libra M" first="Massimo" last="Libra">Massimo Libra</name>
</author>
<author>
<name sortKey="Nicoletti, Ferdinando" sort="Nicoletti, Ferdinando" uniqKey="Nicoletti F" first="Ferdinando" last="Nicoletti">Ferdinando Nicoletti</name>
</author>
<author>
<name sortKey="Drobot, Lyudmyla B" sort="Drobot, Lyudmyla B" uniqKey="Drobot L" first="Lyudmyla B" last="Drobot">Lyudmyla B. Drobot</name>
</author>
<author>
<name sortKey="Franklin, Richard A" sort="Franklin, Richard A" uniqKey="Franklin R" first="Richard A" last="Franklin">Richard A. Franklin</name>
</author>
<author>
<name sortKey="Mccubrey, James A" sort="Mccubrey, James A" uniqKey="Mccubrey J" first="James A" last="Mccubrey">James A. Mccubrey</name>
</author>
</analytic>
<series>
<title level="j">Cell cycle (Georgetown, Tex.)</title>
<idno type="eISSN">1551-4005</idno>
<imprint>
<date when="2011" type="published">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Breast Neoplasms (metabolism)</term>
<term>Breast Neoplasms (pathology)</term>
<term>Breast Neoplasms (radiotherapy)</term>
<term>Breast Neoplasms (therapy)</term>
<term>Cell Culture Techniques (MeSH)</term>
<term>Cell Line, Tumor (MeSH)</term>
<term>Cyclin-Dependent Kinase Inhibitor p21 (metabolism)</term>
<term>Doxorubicin (pharmacology)</term>
<term>Drug Resistance, Neoplasm (MeSH)</term>
<term>Female (MeSH)</term>
<term>Gene Expression Regulation, Neoplastic (MeSH)</term>
<term>Humans (MeSH)</term>
<term>PTEN Phosphohydrolase (genetics)</term>
<term>PTEN Phosphohydrolase (metabolism)</term>
<term>Phosphatidylinositol 3-Kinase (metabolism)</term>
<term>Phosphorylation (MeSH)</term>
<term>Proto-Oncogene Proteins c-akt (genetics)</term>
<term>Proto-Oncogene Proteins c-akt (metabolism)</term>
<term>Radiation Tolerance (MeSH)</term>
<term>Retroviridae (genetics)</term>
<term>Retroviridae (metabolism)</term>
<term>Signal Transduction (MeSH)</term>
<term>Sirolimus (pharmacology)</term>
<term>TOR Serine-Threonine Kinases (antagonists & inhibitors)</term>
<term>TOR Serine-Threonine Kinases (metabolism)</term>
<term>Tamoxifen (pharmacology)</term>
<term>Transfection (MeSH)</term>
<term>Tumor Suppressor Protein p53 (metabolism)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Doxorubicine (pharmacologie)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Inhibiteur p21 de kinase cycline-dépendante (métabolisme)</term>
<term>Lignée cellulaire tumorale (MeSH)</term>
<term>Phosphatidylinositol 3-kinase (métabolisme)</term>
<term>Phosphohydrolase PTEN (génétique)</term>
<term>Phosphohydrolase PTEN (métabolisme)</term>
<term>Phosphorylation (MeSH)</term>
<term>Protéine p53 suppresseur de tumeur (métabolisme)</term>
<term>Protéines proto-oncogènes c-akt (génétique)</term>
<term>Protéines proto-oncogènes c-akt (métabolisme)</term>
<term>Radiotolérance (MeSH)</term>
<term>Retroviridae (génétique)</term>
<term>Retroviridae (métabolisme)</term>
<term>Régulation de l'expression des gènes tumoraux (MeSH)</term>
<term>Résistance aux médicaments antinéoplasiques (MeSH)</term>
<term>Sirolimus (pharmacologie)</term>
<term>Sérine-thréonine kinases TOR (antagonistes et inhibiteurs)</term>
<term>Sérine-thréonine kinases TOR (métabolisme)</term>
<term>Tamoxifène (pharmacologie)</term>
<term>Techniques de culture cellulaire (MeSH)</term>
<term>Transduction du signal (MeSH)</term>
<term>Transfection (MeSH)</term>
<term>Tumeurs du sein (anatomopathologie)</term>
<term>Tumeurs du sein (métabolisme)</term>
<term>Tumeurs du sein (radiothérapie)</term>
<term>Tumeurs du sein (thérapie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en">
<term>TOR Serine-Threonine Kinases</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en">
<term>PTEN Phosphohydrolase</term>
<term>Proto-Oncogene Proteins c-akt</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Cyclin-Dependent Kinase Inhibitor p21</term>
<term>PTEN Phosphohydrolase</term>
<term>Phosphatidylinositol 3-Kinase</term>
<term>Proto-Oncogene Proteins c-akt</term>
<term>TOR Serine-Threonine Kinases</term>
<term>Tumor Suppressor Protein p53</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr">
<term>Tumeurs du sein</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr">
<term>Sérine-thréonine kinases TOR</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en">
<term>Retroviridae</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr">
<term>Phosphohydrolase PTEN</term>
<term>Protéines proto-oncogènes c-akt</term>
<term>Retroviridae</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Breast Neoplasms</term>
<term>Retroviridae</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Inhibiteur p21 de kinase cycline-dépendante</term>
<term>Phosphatidylinositol 3-kinase</term>
<term>Phosphohydrolase PTEN</term>
<term>Protéine p53 suppresseur de tumeur</term>
<term>Protéines proto-oncogènes c-akt</term>
<term>Retroviridae</term>
<term>Sérine-thréonine kinases TOR</term>
<term>Tumeurs du sein</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Doxorubicine</term>
<term>Sirolimus</term>
<term>Tamoxifène</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Doxorubicin</term>
<term>Sirolimus</term>
<term>Tamoxifen</term>
</keywords>
<keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en">
<term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr">
<term>Tumeurs du sein</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en">
<term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr">
<term>Tumeurs du sein</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Cell Culture Techniques</term>
<term>Cell Line, Tumor</term>
<term>Drug Resistance, Neoplasm</term>
<term>Female</term>
<term>Gene Expression Regulation, Neoplastic</term>
<term>Humans</term>
<term>Phosphorylation</term>
<term>Radiation Tolerance</term>
<term>Signal Transduction</term>
<term>Transfection</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Femelle</term>
<term>Humains</term>
<term>Lignée cellulaire tumorale</term>
<term>Phosphorylation</term>
<term>Radiotolérance</term>
<term>Régulation de l'expression des gènes tumoraux</term>
<term>Résistance aux médicaments antinéoplasiques</term>
<term>Techniques de culture cellulaire</term>
<term>Transduction du signal</term>
<term>Transfection</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Elucidating the response of breast cancer cells to chemotherapeutic and hormonal based drugs and radiation is clearly important as these are common treatment approaches. Signaling cascades often involved in chemo-, hormonal- and radiation resistance are the Ras/PI3K/PTEN/Akt/mTOR, Ras/Raf/MEK/ERK and p53 pathways. In the following studies we have examined the effects of activation of the Ras/PI3K/PTEN/Akt/mTOR cascade in the response of MCF-7 breast cancer cells to chemotherapeutic- and hormonal-based drugs and radiation. Activation of Akt by introduction of conditionally-activated Akt-1 gene could result in resistance to chemotherapeutic and hormonal based drugs as well as radiation. We have determined that chemotherapeutic drugs such as doxorubicin or the hormone based drug tamoxifen, both used to treat breast cancer, resulted in the activation of the Raf/MEK/ERK pathway which is often associated with a pro-proliferative, anti-apoptotic response. In drug sensitive MCF-7 cells which have wild-type p53; ERK, p53 and downstream p21 (Cip-1 ) were induced upon exposure to doxorubicin. In contrast, in the drug resistant cells which expressed activated Akt-1, much lower levels of p53 and p21 (Cip1) were induced upon exposure to doxorubicin. These results indicate the involvement of the Ras/PI3K/PTEN/Akt/mTOR, Ras/Raf/MEK/ERK and p53 pathways in the response to chemotherapeutic and hormonal based drugs. Understanding how breast cancers respond to chemo- and hormonal-based therapies and radiation may enhance the ability to treat breast cancer more effectively.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">21869603</PMID>
<DateCompleted>
<Year>2012</Year>
<Month>03</Month>
<Day>19</Day>
</DateCompleted>
<DateRevised>
<Year>2020</Year>
<Month>09</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1551-4005</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>10</Volume>
<Issue>17</Issue>
<PubDate>
<Year>2011</Year>
<Month>Sep</Month>
<Day>01</Day>
</PubDate>
</JournalIssue>
<Title>Cell cycle (Georgetown, Tex.)</Title>
<ISOAbbreviation>Cell Cycle</ISOAbbreviation>
</Journal>
<ArticleTitle>Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.</ArticleTitle>
<Pagination>
<MedlinePgn>3003-15</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Elucidating the response of breast cancer cells to chemotherapeutic and hormonal based drugs and radiation is clearly important as these are common treatment approaches. Signaling cascades often involved in chemo-, hormonal- and radiation resistance are the Ras/PI3K/PTEN/Akt/mTOR, Ras/Raf/MEK/ERK and p53 pathways. In the following studies we have examined the effects of activation of the Ras/PI3K/PTEN/Akt/mTOR cascade in the response of MCF-7 breast cancer cells to chemotherapeutic- and hormonal-based drugs and radiation. Activation of Akt by introduction of conditionally-activated Akt-1 gene could result in resistance to chemotherapeutic and hormonal based drugs as well as radiation. We have determined that chemotherapeutic drugs such as doxorubicin or the hormone based drug tamoxifen, both used to treat breast cancer, resulted in the activation of the Raf/MEK/ERK pathway which is often associated with a pro-proliferative, anti-apoptotic response. In drug sensitive MCF-7 cells which have wild-type p53; ERK, p53 and downstream p21 (Cip-1 ) were induced upon exposure to doxorubicin. In contrast, in the drug resistant cells which expressed activated Akt-1, much lower levels of p53 and p21 (Cip1) were induced upon exposure to doxorubicin. These results indicate the involvement of the Ras/PI3K/PTEN/Akt/mTOR, Ras/Raf/MEK/ERK and p53 pathways in the response to chemotherapeutic and hormonal based drugs. Understanding how breast cancers respond to chemo- and hormonal-based therapies and radiation may enhance the ability to treat breast cancer more effectively.</AbstractText>
<CopyrightInformation>© 2011 Landes Bioscience</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Steelman</LastName>
<ForeName>Linda S</ForeName>
<Initials>LS</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Navolanic</LastName>
<ForeName>Patrick</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chappell</LastName>
<ForeName>William H</ForeName>
<Initials>WH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Abrams</LastName>
<ForeName>Stephen L</ForeName>
<Initials>SL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wong</LastName>
<ForeName>Ellis W T</ForeName>
<Initials>EW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Martelli</LastName>
<ForeName>Alberto M</ForeName>
<Initials>AM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cocco</LastName>
<ForeName>Lucio</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Stivala</LastName>
<ForeName>Franca</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Libra</LastName>
<ForeName>Massimo</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nicoletti</LastName>
<ForeName>Ferdinando</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Drobot</LastName>
<ForeName>Lyudmyla B</ForeName>
<Initials>LB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Franklin</LastName>
<ForeName>Richard A</ForeName>
<Initials>RA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>McCubrey</LastName>
<ForeName>James A</ForeName>
<Initials>JA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 CA098195</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA098195</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2011</Year>
<Month>09</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cell Cycle</MedlineTA>
<NlmUniqueID>101137841</NlmUniqueID>
<ISSNLinking>1551-4005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050759">Cyclin-Dependent Kinase Inhibitor p21</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C495901">TP53 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>094ZI81Y45</RegistryNumber>
<NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>80168379AG</RegistryNumber>
<NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.137</RegistryNumber>
<NameOfSubstance UI="D058539">Phosphatidylinositol 3-Kinase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.67</RegistryNumber>
<NameOfSubstance UI="D051059">PTEN Phosphohydrolase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.67</RegistryNumber>
<NameOfSubstance UI="C494929">PTEN protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>W36ZG6FT64</RegistryNumber>
<NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
<QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018929" MajorTopicYN="N">Cell Culture Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D050759" MajorTopicYN="N">Cyclin-Dependent Kinase Inhibitor p21</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051059" MajorTopicYN="N">PTEN Phosphohydrolase</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D058539" MajorTopicYN="N">Phosphatidylinositol 3-Kinase</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011836" MajorTopicYN="N">Radiation Tolerance</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012190" MajorTopicYN="N">Retroviridae</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013629" MajorTopicYN="N">Tamoxifen</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2011</Year>
<Month>8</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2011</Year>
<Month>8</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2012</Year>
<Month>3</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">21869603</ArticleId>
<ArticleId IdType="pii">17119</ArticleId>
<ArticleId IdType="pmc">PMC3218601</ArticleId>
<ArticleId IdType="doi">10.4161/cc.10.17.17119</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Cancer Cell. 2004 Aug;6(2):117-27</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15324695</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Biol. 1992 Nov;12(11):5041-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1406679</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 1993 Aug;8(8):2183-91</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7687761</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 1996 Dec 6;271(49):31372-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8940145</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 1997 Jan 31;275(5300):665-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9005852</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Curr Biol. 1997 Apr 1;7(4):261-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9094314</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 1997 Jul 25;277(5325):567-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9228007</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 1997 Oct 31;91(3):325-34</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9363941</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Genes Chromosomes Cancer. 1998 Feb;21(2):166-71</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9491329</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Neurosci. 1999 Feb 15;19(4):1179-88</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9952396</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Biol. 1999 Mar;19(3):1751-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10022862</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2004 Dec 1;10(23):8059-67</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15585641</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Expert Opin Ther Targets. 2004 Dec;8(6):537-50</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15584861</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncology. 2005;68(4-6):398-404</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16020969</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Expert Opin Ther Targets. 2005 Oct;9(5):1009-30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16185155</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Br J Cancer. 2005 Dec 12;93(12):1372-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16288304</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2005 Oct;4(10):1309-12</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16131837</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2006 Feb 15;66(4):2028-37</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16489002</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Br J Cancer. 2006 Jun 5;94(11):1678-82</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16721365</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Breast Cancer. 2006;13(2):137-44</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16755107</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2007 Mar 1;6(5):595-605</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17351335</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2007 Nov 1;67(21):10466-74</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17974990</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 2008 Mar 13;27(12):1749-58</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17891174</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2008 Apr 15;7(8):965-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18414037</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2008 Apr 15;7(8):1020-35</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18414053</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 2008 Jul 3;27(29):4086-95</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18332865</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Leukemia. 2008 Nov;22(11):2080-90</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18685611</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Leukemia. 2009 Jan;23(1):25-42</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18800146</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2009 Jan 1;8(1):18-22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19106609</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2009 Feb 1;8(3):403-13</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19177005</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2009 Feb 15;8(4):560-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19197152</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2009 Mar 1;8(5):731-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19221485</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2009 Mar 15;8(6):909-15</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19221498</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2009 Apr 1;8(7):1003-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19270523</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2009 Apr 15;8(8):1196-205</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19305158</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2009 May 1;8(9):1352-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19305151</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2009 May 15;8(10):1589-602</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19377290</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2009 May 15;69(10):4252-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19435898</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Thorac Oncol. 2009 Jun;4(6):761-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19404218</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2009 Jun 15;8(12):1883-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19448395</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2009 Jun 15;8(12):1888-95</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19471117</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2009 Jun 15;8(12):1901-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19471118</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2009 Jun 15;8(12):1896-900</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19478560</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS Biol. 2009 Jun 2;7(6):e1000121</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19492080</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2009 Jul 15;8(14):2198-210</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19502790</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2009 Aug 15;8(16):2502-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19597332</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2009 Aug 15;8(16):2518-22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19625770</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2009 Sep 1;8(17):2728-32</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19652529</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2009 Oct 1;8(19):3208-17</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19738435</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2009 Nov 15;8(22):3707-16</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19844169</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2009 Nov 15;8(22):3777-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19855165</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2009 Dec;8(23):3831-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19901542</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2009 Dec;8(23):3878-84</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19901535</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2009 Dec;8(23):3893-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19934662</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2010 Jan 1;9(1):188-97</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20016287</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nephrol Dial Transplant. 2010 Feb;25(2):373-80</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19828461</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Aging (Albany NY). 2009 Oct;1(10):845-54</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20157557</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Aging (Albany NY). 2009 Nov;1(11):887-902</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20157573</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Aging (Albany NY). 2009 May;1(5):490-502</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20157532</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Aging (Albany NY). 2009 Jun;1(6):515-28</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20157535</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Aging (Albany NY). 2009 Jun;1(6):542-56</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20157537</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Aging (Albany NY). 2009 Jun;1(6):582-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20157540</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2010 Feb 1;9(3):487-97</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20081374</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2010 Feb 1;9(3):596-600</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20009532</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Adv Enzyme Regul. 2010;50(1):285-307</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19895837</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2010 May 25;107(21):9660-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20457898</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2010 May;9(9):1839-46</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20436269</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2010 May;9(9):1781-91</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20436278</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Biother Radiopharm. 2010 Jun;25(3):317-23</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20578837</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Aging (Albany NY). 2010 Jun;2(6):344-52</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20606252</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochim Biophys Acta. 2010 Sep;1803(9):991-1002</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20399811</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Aging (Albany NY). 2010 Aug;2(8):471-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20729567</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2010 Aug 15;9(16):3151-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20724817</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2010 Aug 15;9(16):3213-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20814244</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2010 Sep 1;9(17):3460-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20855954</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2010 Sep 15;9(18):3780-91</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20855963</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2010 Nov 1;9(21):4269-75</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20980816</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Aging (Albany NY). 2010 Oct;2(10):691-708</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21037379</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2010 Nov 15;9(22):4450-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21084866</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Aging (Albany NY). 2010 Nov;2(11):760-74</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21084729</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Aging (Albany NY). 2010 Dec;2(12):924-35</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21212465</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Aging (Albany NY). 2010 Dec;2(12):908-13</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21164221</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncotarget. 2010 Jun;1(2):89-103</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20671809</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncotarget. 2010 Jun;1(2):156-60</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21297225</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncotarget. 2010 Oct;1(6):387-95</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21311095</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 2011 Feb 24;30(8):944-55</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20956948</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Trends Pharmacol Sci. 2011 Mar;32(3):131-40</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21236500</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Aging (Albany NY). 2011 Mar;3(3):192-222</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21422497</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncotarget. 2011 Mar;2(3):135-64</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21411864</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Adv Enzyme Regul. 2011;51(1):152-62</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21035484</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2010 Mar 15;9(6):1194-206</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20237414</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2010 Apr 15;9(8):1629-38</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20372086</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncotarget. 2011 Jun;2(6):435-47</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21646685</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Leukemia. 2011 Jul;25(7):1064-79</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21436840</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Leukemia. 2011 Jul;25(7):1080-94</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21494257</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Cell Physiol. 2011 Nov;226(11):2762-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21302297</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 1999 Nov 26;286(5445):1741-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10576742</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Neurosci. 2000 Mar 1;20(5):1694-700</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10684871</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Growth Differ. 2000 Jun;11(6):279-92</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10910095</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell. 2001 Feb;7(2):283-92</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11239457</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2001 Sep;7(9):2898-907</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11555608</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Hum Pathol. 2002 Apr;33(4):405-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12055674</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 2002 Aug 23;277(34):31099-106</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12048182</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cancer Ther. 2002 Jul;1(9):707-17</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12479367</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2003 Mar;9(3):1161-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12631622</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 2003 Apr 24;22(16):2478-92</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12717425</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2003 Aug 1;9(8):2933-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12912939</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell. 2004 May 21;14(4):501-13</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15149599</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>Caroline du Nord</li>
</region>
</list>
<tree>
<noCountry>
<name sortKey="Abrams, Stephen L" sort="Abrams, Stephen L" uniqKey="Abrams S" first="Stephen L" last="Abrams">Stephen L. Abrams</name>
<name sortKey="Chappell, William H" sort="Chappell, William H" uniqKey="Chappell W" first="William H" last="Chappell">William H. Chappell</name>
<name sortKey="Cocco, Lucio" sort="Cocco, Lucio" uniqKey="Cocco L" first="Lucio" last="Cocco">Lucio Cocco</name>
<name sortKey="Drobot, Lyudmyla B" sort="Drobot, Lyudmyla B" uniqKey="Drobot L" first="Lyudmyla B" last="Drobot">Lyudmyla B. Drobot</name>
<name sortKey="Franklin, Richard A" sort="Franklin, Richard A" uniqKey="Franklin R" first="Richard A" last="Franklin">Richard A. Franklin</name>
<name sortKey="Libra, Massimo" sort="Libra, Massimo" uniqKey="Libra M" first="Massimo" last="Libra">Massimo Libra</name>
<name sortKey="Martelli, Alberto M" sort="Martelli, Alberto M" uniqKey="Martelli A" first="Alberto M" last="Martelli">Alberto M. Martelli</name>
<name sortKey="Mccubrey, James A" sort="Mccubrey, James A" uniqKey="Mccubrey J" first="James A" last="Mccubrey">James A. Mccubrey</name>
<name sortKey="Navolanic, Patrick" sort="Navolanic, Patrick" uniqKey="Navolanic P" first="Patrick" last="Navolanic">Patrick Navolanic</name>
<name sortKey="Nicoletti, Ferdinando" sort="Nicoletti, Ferdinando" uniqKey="Nicoletti F" first="Ferdinando" last="Nicoletti">Ferdinando Nicoletti</name>
<name sortKey="Stivala, Franca" sort="Stivala, Franca" uniqKey="Stivala F" first="Franca" last="Stivala">Franca Stivala</name>
<name sortKey="Wong, Ellis W T" sort="Wong, Ellis W T" uniqKey="Wong E" first="Ellis W T" last="Wong">Ellis W T. Wong</name>
</noCountry>
<country name="États-Unis">
<region name="Caroline du Nord">
<name sortKey="Steelman, Linda S" sort="Steelman, Linda S" uniqKey="Steelman L" first="Linda S" last="Steelman">Linda S. Steelman</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001300 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001300 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    RapamycinFungusV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:21869603
   |texte=   Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:21869603" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a RapamycinFungusV1 

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 21:55:41 2020. Site generation: Thu Nov 19 22:00:39 2020